Lung autoantibodies: Ready for prime time?

Area of Science:

• Immunology
• Transplantation Science
• Allograft Pathology

Background:

• Contemporary immunosuppression has reduced acute lung allograft rejection but not chronic lung allograft dysfunction (CLAD).
• CLAD, especially the restrictive phenotype, significantly reduces long-term survival after lung transplantation.
• The International Society for Heart and Lung Transplantation consensus highlights the need for standardized approaches to antibody-mediated rejection.

Discussion:

• Antibody-mediated rejection (AMR) is increasingly recognized as a critical factor in CLAD.
• Both human leukocyte antigen (HLA) and non-HLA antibodies contribute to allograft injury.
• Understanding the role of non-HLA antibodies is crucial for improving lung allograft outcomes.

Key Insights:

• Non-HLA antibodies are implicated in lung allograft injury and dysfunction.
• A uniform diagnostic and management strategy for antibody formation is needed.
• Focusing on non-HLA antibody-related mechanisms is essential for advancing lung transplantation.

Outlook:

• Further research into non-HLA antibody targets and mechanisms is warranted.
• Developing targeted therapies against non-HLA antibodies may improve CLAD management.
• This perspective guides future research and clinical practice in lung allograft tolerance and rejection.